Shares of Aktis Oncology (NASDAQ:AKTS – Get Free Report) were up 7.4% on Tuesday . The company traded as high as $19.49 and last traded at $19.6150. Approximately 14,076 shares traded hands during trading, a decline of 96% from the average daily volume of 326,991 shares. The stock had previously closed at $18.27.
Analyst Ratings Changes
A number of brokerages recently commented on AKTS. HC Wainwright raised their target price on Aktis Oncology from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Bank of America assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price objective for the company. Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, TD Cowen started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating for the company. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $32.00.
Get Our Latest Stock Analysis on Aktis Oncology
Aktis Oncology Stock Up 5.3%
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last posted its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The firm had revenue of $1.87 million for the quarter. As a group, equities research analysts expect that Aktis Oncology will post -1.44 EPS for the current fiscal year.
Aktis Oncology Company Profile
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Featured Articles
- Five stocks we like better than Aktis Oncology
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
- Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?
- Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
